In February 2017 the companies inked a 5-year deal calling for Medtronic to distribute the Chocolate PTA device. Last May the Fridley, Minn.-based medical device giant agreed to the option deal on Chocolate PTA, which was triggered in part after QT Vascular successfully shifted production to a third-party contract manufacturer.
“Through our distribution agreement with QT Vascular, we have seen a lot of excitement from physicians about this unique, specialty balloon,” peripheral GM Mark Pacyna said in prepared remarks. “The acquisition of the Chocolate PTA balloon will strengthen our portfolio, providing customers with a both a stand-alone and adjunctive treatment option for peripheral artery disease above and below the knee.”
“We are very pleased with the completion of the sale of our non-drug coated peripheral product, the Chocolate PTA balloon catheter, to Medtronic, the world’s leading medical device company,” added QT Vascular CEO Eitan Konstantino. “This is a validation of the intrinsic value of our internally developed products.”
QT Vascular has said it still plans to develop a drug-coated version of the device called Chocolate Touch, which is the subject of a pivotal trial after winning an investigational device exemption from the FDA last year. The company said it also plans to continue working on its portfolio of coronary products.
In March 2017 QT Vascular signed a private placement deal with Gem Global Yield Fund for up to $14.3 million (SGD $20 million) over the following 30 months.
Early rates for DeviceTalks Boston end August 15th.
Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.
View Full Agenda
Register today to save. Use code LASTCALL to save an additional 10%.